Aims To compare morbidity and mortality in opioid dependence patients following the commencement of treatment with the general population.
Introduction
International studies have consistently shown that mortality rates among illicit opioid users are significantly greater (~13 times) than that of the general population with very high rates of accidental overdose, suicide, accidents and homicide. 1 Similarly high rates of non-fatal poisoning, intentional self-harm, mental illness, infections including blood borne and sexually transmissible diseases are also commonly observed in opioid dependent patients. [2] [3] [4] More recently, the chronic use of opioids has also been associated with a range of causes and conditions not commonly associated with heroin dependence or its lifestyle, including chronic and agerelated morbidity such as arthritis, 5 reduced bone mineral density, 6, 7 end-stage renal disease, 8 increased vascular age and arterial stiffness 9 and coronary artery disease. 10, 11 The treatment of opioid dependent patients has been shown to significantly improve their overall health and reduce lifestyle and drug related morbidity and mortality, [12] [13] [14] although less in known about chronic or age related morbidity such as vascular, respiratory and coronary disease. Further, little data is available comparing treatment and post-treatment morbidity and mortality in opioid dependent patients to nondependent members of the general public.
This research identified and quantified a broad range of morbidity and mortality in opioid dependent patients following entry into an opioid pharmacotherapy (methadone, Erin Kelty, Research Associate Gary Hulse, Professor of Addiction Biology buprenorphine or implant naltrexone) treatment, and compares rates of morbidity and mortality with an age and gender matched cohort of non-dependent controls.
Methods

Subjects
All opioid dependent patients over the age of 18 treated in Western Australia (WA) with methadone, buprenorphine or implant naltrexone for the first time between January 2001 and December 2010 were recruited in the study. Participants treated with methadone and/or buprenorphine (both buprenorphine alone and in combination with naloxone) were identified from the Monitoring of Drugs of Dependence System (MODDS). The naltrexone cohort was obtained from clinic records for the sole provider of implant naltrexone in the state during this period. A cohort of age (5-year age bracket) and gender matched controls were selected from the electoral roll, by the WA Data Linkage Branch (DLB). The cohort was matched against the MODDS system to ensure controls had not been treated with methadone prior to 2001.
Data linkage
Identifying information for the two cohorts was probabilistically matched against the Death Registrations, the Hospital Morbidity Data Collection, the Emergency Department Data Collection and the WA Notifiable Infectious Diseases Database by the Data Linkage Branch. The de-identified data was provided to the research group, with records from 1999 to 2012, with the exception of Emergency Department (ED) data which was only available from 2002 onwards.
Analysis
Opioid dependent patients and the non-dependent controls were matched 1 to 1. Opioid dependent patients were deemed to have entered the study at the commencement of their first treatment. Both groups were censored at time of death (if applicable) or the 31st of December 2012.
Crude mortality rates were calculated for both cohorts and expressed per 1000 patient years (ptpy). Comparisons between the two cohorts were performed using univariate Cox proportional hazard regression. Additionally, rates of gender, age and cause-specific mortality were also calculated for the two cohorts. Cause-specific mortality rates included opioid poisoning (T40.0-T40.4), non-opioid drug and alcohol poisoning (T36-39.9, T40.5-51), suicide (X60-X84, Y87.0), respiratory disease (J00-J99), cardiovascular disease (I00-I99), traffic/transport related (V00-V99) and cancer (C00-C99). Univariate cox proportional hazard regression was used to compare mortality rates.
Crude rates of hospital admissions and ED attendances were calculated for opioid dependent patients and the control cohort and expressed ptpy. Additionally, rates of gender and age (age at commencement) rates of hospital admission and ED attendances were calculated, as well as rates of cause-specific hospital admissions and rates of priority/ severity of ED attendances. Rates of cause-specific hospital admissions were identified using primary, co-diagnoses and additional diagnoses (up to 20 additional diagnoses) assigned to each admission coded using ICD-10-AM codes. Types of hospital admissions examined included opioid poisoning (ICD-10-AM T40.0-40.4), non-opioid drug poisoning (T36-39.9, T40.5-51), mental health (F00-09; F20-99), intentional selfharm (X60-84, Y87.0), blood (D50-89), cardiovascular (I00-99), digestive (K00-93), endocrine/nutritional/metabolic (E00-90), genitourinary (N00-99), infection (A00-99; B00-99), musculoskeletal (M00-99), nerve (G00-99), respiratory (J00-99) and traffic/transport (V00-99). Priority/severity of ED attendances were categories using the Australasian Triage Scale [1] [2] [3] [4] [5] assigned to each attendances. 15 Rates of hospital admissions and ED attendances in opioid and non-opioid dependent patients were compared using generalized linear models with a negative binomial distribution.
Life-time prevalence of patients diagnoses with blood borne viruses (hepatitis B and C) and sexually transmissible diseases (chlamydia, gonorrhea and syphilis) were calculated for the opioid and non-opioid dependent patients and compared using univariate logistic regression.
Results
Demographics
The study was comprised of 5646 opioid dependent patients who entered onto pharmacotherapy treatment for opioid dependence with methadone, buprenorphine and/or implant naltrexone between 2001 and 2010, and a cohort of 5646 age (5-year age bracket) and gender matched controls. At the commencement of the study, the average age was 31.5 ± 8.6 years (opioid: 31.5 ± 8.6 years, control: 31.5 ± 8.7 years) and males represented 65.8% of the study population.
Mortality
Compared with the control group, the risk of mortality in opioid dependent patients was significantly elevated following the commencement of treatment (hazard ratio (HR) = 8.81, 95% CI: 6.26-12.38) (Fig. 1) . While both males and female opioid dependent patients showed significant elevation in mortality compared with the non-dependent controls, female patients had the largest risk of mortality, with 15.33 times the risk compared with non-dependent controls, while the risk in opioid dependent males was 7.55 times greater than the control group (Table 1) .
As age increased, so too did mortality rates. However, the hazard ratio comparing opioid dependent patients to nondependent controls reduced, with a HR of 11.20 for participants aged 18-25, 10.55 for participants aged 26-35, 7.36 for participants age 36-45 and 5.71 for participants aged 46 and over.
The leading causes of mortality in opioid dependents was opioid poisoning (37.3%/2.8 ptpy), followed by non-opioid drug poisoning (35.7% of deaths and 2.7 ptpy), and suicide (14.3%/1.1 ptpy). In contrast, the leading cause of mortality in the control group was cardiovascular (35.1%/0.3 ptpy), cancer (29.7%/0.3 ptpy) and respiratory (13.5/0.1 ptpy) diseases/disorders. Compared with the control groups, high rates of mortality associated with opioid overdoses, nonopioid drug overdoses, suicide, respiratory, cardiovascular, traffic and those with no known cause of death was observed in opioid dependent patients.
Hospital admissions
Following the commencement of treatment, opioid dependent patients were hospitalized at approximately twice the rate of the control group (Table 2) . While rates of hospital admissions were significantly elevated across all causes examined, rates of hospital admissions with a diagnosis of opioid poisoning, non-opioid drug poisoning, intention selfharm and mental health diagnoses exhibited the largest difference in comparison to the control group. In both opioid dependent patients and non-opioid dependent patients, rates of hospitalization were significantly elevated in female patients compared with males (risk ratio (RR) = 1.57, 95% CI: 1.43-1.71 and RR = 1.71, 95% CI: 1.61-1.89, respectively).
ED attendances
As per hospital admissions, post-treatment entry rates of ED attendances were significantly elevated in the opioid dependent patients compared with the control group (Table 3) with female patients in both cohorts having higher rates of ED attendance compared with males (opioid RR = 1.32, 95% CI: 1.22-1.43 and control RR = 1.16, 95% CI: 1.06-1.27) ( Table 3) .
Reportable infectious diseases
Life-time prevalence of both HBV and HCV were significantly elevated in opioid dependent patients compared with non-dependent patients. Rates of chlamydia and gonorrhea were also significantly elevated, however, rates of syphilis in opioid dependent patients were not different to the control group (Table 4) . 
MORBIDITY IN TREATED OPIOID USERS
Discussion
Main findings of this study
In this study, the risk of morbidity and mortality in opioid dependent patients was shown to be significantly elevated compared with non-dependent age and gender match controls. Opioid and non-opioid drug poisoning, intentional self-harm, mental health disorders and hepatitis C were all large contributors to the elevated rates of morbidity in opioid dependent patients. However the study also observed high rates of morbidity and mortality associated with a number of other diseases/disorders including chlamydia, gonorrhea, cardiovascular, respiratory, nerve and genitourinary, which are less frequently associated with opioid use.
What is already known on this topic
It is generally accepted that morbidity and mortality in heroin dependent persons is greater than non-dependent members of the community, and that entry into pharmacotherapy treatment is associated with reduction in morbidity and mortality. 12, 13 High rates of non-fatal poisoning, intentional self-harm, mental illness, accidents, homicide, infections including blood borne and sexually transmissible diseases have been commonly observed in opioid dependent patients as a result of opioid use and other risk factors often associated with opioid use. [1] [2] [3] [4] It has also been hypothesized that opioids accelerate biological aging. On a cellular level, abstinent heroin users have been shown to have significantly lower telomerase activity (an indicator of cellular aging) relative to healthy controls. 16 Clinically, opioid dependent patients have also been observed to have higher measures of arterial stiffness (an age related cardiovascular risk factor), 17 exhibit earlier temporal and vertical hair graying, and have poorer dental and psychological health (also associated with aging). 18 Gender difference in morbidity and mortality have been previously observed and are usually explained by differences in biological risks, acquired risks and experiences in healthcare. 19 An examination of health differences by MacIntyre et al., 19 observed excess morbidity in female patients in terms of psychological manifestations of distress compared with males, however, in terms of physical symptoms or conditions there was generally minimal difference and in some cases the reverse was observed.
What this study adds
While other studies have shown a reduction in poor health outcomes following entry onto treatment, this study suggests that large disparities still exist between opioid dependent patients following the commencement of treatment and the general public. Importantly, these opioid dependent patients had already initiated contact with a treatment provider, as such treatment services could play an essential role in the delivery of services and interventions to reduce subsequent morbidity. Given the diversity in the types of morbidity and mortality observed, it is clear that an integrated healthcare approach is required for the treatment and management of opioid dependent patients both on treatment and following treatment. Targets for reducing mortality should focus on opioid poisoning, non-opioid drug poisoning and suicide, which were the three largest categories of mortality and were vastly over represented compared with the control group. For reducing the burden on morbidity, mental health appears to be a very important factor which could significantly reduce rates of hospitalization. Additionally, to reduce the burden of opioid dependent patients on ED services, low priority attendances (triage codes 4 and 5) could be targeted. Such could be achieved by extending current GP services for opioid dependent patients including extending operating hours, and allowing 'walk-in' patients to redirect patients away from ED services. This may also encourage patients to seek medical advice rather than waiting until an issue becomes more severe.
The difference in age and gender morbidity and mortality raises the question as to whether treatment services should be more specifically tailored to take into account these differences. Older patients may require different services compared with younger patients, similarly female patients whose experience with opioid dependence is likely to be different to males (i.e. pregnancy, prostitution, domestic violence, child custody issues) are likely to require different treatment services and systems to their male counterparts.
Limitations of this study
Study data was limited to events that occurred within WA, thus morbidity and mortality occurring interstate or overseas would not have been included. This is particularly important for patients who may have moved during follow-up. Therefore rates of mortality, hospitalization and ED attendance should be considered a minimum. However given rates of movement in and out of WA is generally considered minimal due to its isolation, this issue is likely to have only a very small impact on the data integrity. Similarly rates of reportable infectious diseases should be considered an estimate, as although routine testing is generally carried out at the commencement of treatment, not all patients may have been tested. Additionally they may have contracted diseases after commencing treatment or the disease may not yet have been detectable due to recent transmission (i.e. HCV).
The study looks only very broadly at the categories of type-specific morbidity and mortality and not individual diagnoses. 
Conclusions
Following the commencement of treatment for opioid dependence, patients are still at a very high risk of morbidity and mortality compared with non-opioid dependent persons. Efforts to reduce this morbidity and mortality reach across a wide range of diseases and disorders.
